Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals (WHIP3TB)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02980016 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 2, 2016
Last Update Posted : May 8, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Tuberculosis HIV | Drug: rifapentine + isoniazid Drug: Isoniazid | Phase 3 |
Part A: A randomised controlled trial of 3HP vs 6H [enrollment starts concurrently with Part B]
Justification: The World Health Organization (WHO) recommends at least six months of isoniazid (6H) for persons living with HIV. However, 6H remains poorly implemented in most high burden tuberculosis (TB) countries. In its 2015 guidelines, WHO includes 3HP as an latent tuberculosis infection (LTBI) treatment option for high-income and upper middle-income countries with TB incidence rates <100/100,000. One trial comparing 3HP to 6H in a high burden country suggests that a single round of 3HP has less toxicity, better treatment completion rates, and similar efficacy in preventing TB. The purpose of comparing a single round of 3HP to 6H is to demonstrate the feasibility of implementing 3HP in high burden countries, to explore its safety and effectiveness, and to generate evidence to guide a WHO recommendation for the use of 3HP in high burden settings.
Sample size: If we assume 85% of patients in the 6H arm complete treatment as defined above, with 400 patients in the 6H arm and 3600 patients in the 3HP arm we will have 82% power to detect an increase in treatment completion of 5% (To -90%) in the 3HP arm. If treatment completion in the 6H arm is 75%, we will have approximately 90% power to detect an increase in treatment completion of 7% in the 3HP arm.
Analysis: Treatment completion will be compared by study arm using Fishers Exact test, and associated risk difference and 95% confidence interval (CI).
Part B: A randomised controlled trial of 3HP vs p3HP [enrollment starts concurrently with Part A]
Justification: A single round of 3HP has been shown to be non-inferior to 9 months of isoniazid (9H) in persons at high risk of developing TB in low and middle TB burden settings. Similarly, a single round of 3HP has demonstrated similar efficacy in preventing active TB when compared to 6H among HIV-positive, tuberculin skin test (TST)-positive adults in the high burden setting of South Africa. In high burden settings, 6H and 3HP provide protection of limited duration probably due to high ongoing transmission and reinfection. Continuous isoniazid preventive therapy has been shown to provide more durable protection in high burden settings, but is not currently policy outside of a handful of countries, and the actual uptake is poor. Giving 3HP periodically may provide durable protection, be easier for health systems to implement, and may be associated with better adherence and fewer side effects.
Sample size: Assuming a cumulative TB incidence of 5% over 2 years in the control (3HP) arm, an overall loss to follow-up of 10% by year 2, a two-sided type I error of 5%, 1:1 randomisation, a superiority comparison and 1800 participants per arm, we have 80% power to detect a 40% reduction in cumulative TB incidence from months 0 to 24.
Analysis: The analysis will compare 3HP and p3HP with two years of follow up. Cumulative TB incidence will be determined by combining incident TB cases identified over the 24 months of follow up AND prevalent TB cases identified at the 12 and 24 month culture survey. Data will be reported as a risk difference and odds ratio and their associated 95% CIs, adjusting for randomisation strata. The secondary outcome comparing the effectiveness of p3HP to 3HP from month 13 to 24 (during which time the greatest effect is likely to be evident) will be conducting using the same analytic methods. The results of Part B will be disseminated subsequent to the results of Part A.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 4027 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | A Randomised, Pragmatic, Open-Label Trial To Evaluate The Effect Of Three Months Of High Dose Rifapentine Plus Isoniazid Administered As A Single Round Or Given Annually In HIV-Positive Individuals |
| Actual Study Start Date : | November 2016 |
| Estimated Primary Completion Date : | September 2019 |
| Estimated Study Completion Date : | September 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: 3HP (rifapentine + isoniazid)
Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Year 1
|
Drug: rifapentine + isoniazid
Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
Other Name: Priftin (rifapentine) |
|
Active Comparator: p3HP (rifapentine + isoniazid)
Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Years 1 and 2
|
Drug: rifapentine + isoniazid
Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
Other Name: Priftin (rifapentine) |
|
Active Comparator: 6H
Daily self-administered isoniazid (at a dose of 300 mg/daily) (with adjustment for participants weighing ≤24 kg) given for 26 weeks (6 months) in Study Year 1
|
Drug: Isoniazid
Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
Other Name: Winthrop (isoniazid) |
- Treatment completion (part A) [ Time Frame: 1 year ]
Number of participants without evidence of active TB at enrollment who complete treatment, defined as:
Proportion of participants in 3HP group self-reporting treatment completion of ≥11 doses in a 16-week period
; Proportion or participants in 6H group self-reporting treatment completion of ≥167 doses over an 34 week (8-month) period
- TB incidence (part B) [ Time Frame: 2 years ]Number of participants without evidence of active TB at enrollment who are diagnosed with active TB meeting the definition: Confirmed tuberculosis: Culture-positive, Xpert MTB/RIF-positive, or smear-positive for M. tuberculosis from any site in adults and children OR Clinical tuberculosis: Started on treatment for TB in adults and children
- TB incidence (part A) [ Time Frame: 1 year ]Number of participants without evidence of active TB at enrollment who are diagnosed with active TB meeting the definition: Confirmed tuberculosis: Culture-positive, Xpert MTB/RIF-positive, or smear-positive for M. tuberculosis from any site in adults and children OR Clinical tuberculosis: Started on treatment for TB in adults and children
- All-cause mortality (part A) [ Time Frame: 1 year ]Number of participants without evidence of active TB at enrollment who die from any cause
- Permanent discontinuation of therapy due to treatment-related adverse events (part A) [ Time Frame: 1 year ]Number of participants without evidence of active TB at enrollment who permanently discontinue therapy due to an adverse drug reaction
- TB incidence (part B) [ Time Frame: 1 year ]Number of participants without evidence of active TB during enrollment who are diagnosed with active TB meeting during the second year of follow-up. The definition of active TB is: Confirmed tuberculosis: Culture-positive, Xpert MTB/RIF-positive, or smear-positive for M. tuberculosis from any site in adults and children OR Clinical tuberculosis: Started on treatment for TB in adults and children
- Treatment completion (part B) [ Time Frame: 2 years ]Number of participants without evidence of active TB at enrollment who complete treatment, defined as: Proportion of participants in 3HP group self-reporting treatment completion of ≥11 doses in a 16-week period; Proportion or participants in p3HP group self-reporting treatment completion of ≥22 doses over two annual 16-week periods
- All-cause mortality (part B) [ Time Frame: 2 years ]Number of participants without evidence of active TB at enrollment who die from any cause
- Permanent discontinuation of therapy due to treatment-related adverse events (part B) [ Time Frame: 2 years ]Number of participants without evidence of active TB at enrollment who permanently discontinue therapy due to an adverse drug reaction
- Cost per TB case prevented [ Time Frame: 2 years ]Cost per TB case prevented
- Cost per death averted [ Time Frame: 2 years ]Cost per death averted
- Cost per disability adjusted life year (DALY) averted by study arm [ Time Frame: 2 years ]Cost per disability adjusted life year (DALY) averted by study arm
- IGRA conversions (part A) [ Time Frame: 1 year ]Number of IGRA-negative participants without evidence of active TB at enrollment with the occurrence of IGRA conversions at the end of year 1
- IGRA reversions (part A) [ Time Frame: 1 year ]Number of IGRA-positive participants without evidence of active TB at enrollment with the occurrence of IGRA reversions at the end of year 1
- Incidence of TB resistant to isoniazid and/or rifapentine [ Time Frame: 2 years ]Number of individuals without evidence of active TB at enrollment who are diagnosed with active TB resistant to isoniazid and/or rifapentine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- At least two years of age
- Known HIV infection
- Antiretroviral therapy (ART) ineligible or on ART for ≥3 months
Exclusion Criteria:
- Confirmed or suspected TB disease
- Likely to move from the study area during the study period
- Known exposure to TB cases with known or suspected resistance to isoniazid or rifampicin in the source case
- TB treatment within the past year
- TB preventive therapy within the last year
- Sensitivity or intolerance to isoniazid or rifamycins
- Suspected acute hepatitis or known chronic liver disease
- ALT/AST >5 times the upper limit of normal (regardless of symptoms of hepatitis)
- Pregnancy or breastfeeding
- Women of childbearing potential who are unable or unwilling to use contraception
- Self-reported alcohol use exceeding 28 units per week for men, or 21 units for women
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02980016
| South Africa | |
| The Aurum Institute NPC | |
| Johannesburg, Gauteng, South Africa, 2193 | |
| Principal Investigator: | Gavin Churchyard, MBBCh, PhD | Aurum Institute |
Publications:
| Responsible Party: | The Aurum Institute NPC |
| ClinicalTrials.gov Identifier: | NCT02980016 History of Changes |
| Other Study ID Numbers: |
3HP-AUR1-1-170 |
| First Posted: | December 2, 2016 Key Record Dates |
| Last Update Posted: | May 8, 2018 |
| Last Verified: | April 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
Additional relevant MeSH terms:
|
Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Isoniazid Rifapentine Rifampin Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Fatty Acid Synthesis Inhibitors Hypolipidemic Agents |
Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Antibiotics, Antitubercular Leprostatic Agents Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP2C8 Inducers Cytochrome P-450 CYP2C19 Inducers Cytochrome P-450 CYP2C9 Inducers Cytochrome P-450 CYP3A Inducers |